The group's principal activity is the development of humanized monoclonal antibodies for the treatment of diseases. The key areas of disease focus include oncology and inflammatory and autoimmune diseases. It has several humanized antibodies in clinical development for inflammatory bowel disease, psoriasis and asthma. The group has licensed certain rights to first humanized antibody product, zenpax to hoffmann-la roche inc and its affiliates, which markets it for the prevention of kidney transplant rejection.the groups registered trademarks are protein design labs, nuvion and humanizing science. The group operates mainly in the domestic market. On 04-Apr-2003, the group acquired eos biotechnology inc.
